ASCO GI 2023: NAPOLI-3 Trial in Metastatic Pancreatic Ductal Adenocarcinoma
Posted: 02/08/2023 | By: Sarah Campen, PharmD

At the 2023 ASCO Gastrointestinal Cancers Symposium, Wainberg et al presented results from NAPOLI-3, a randomized, open-label, phase III study investigating the efficacy and safety of NALIRIFOX compared with nab-paclitaxel plus gemcitabine as first-line therapy in patients with metastatic pancreatic cancer (Abstract LBA661).

Question 1 of 5

The treatment regimen NALIRIFOX includes:

Choose 1